Caris Life Sciences (CAI) Stock Price, News & Analysis

Company Overview

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis. In addition to clinical testing for patient care, the company offers translational science and clinical trial support services to biopharmaceutical partners, including biomarker discovery, assay development and companion diagnostic collaborations to facilitate drug development programs.

The company primarily serves healthcare providers, cancer centers and biopharma customers in the United States and through international collaborations. Its offerings are used across the oncology care continuum—from initial profiling to inform therapy selection through longitudinal monitoring and research applications—positioning the business at the intersection of clinical diagnostics and precision oncology research.

Caris emphasizes the integration of multi‑omic data and computational analysis to generate clinically actionable insights, and it engages with clinicians, researchers and industry partners to expand the use of molecular profiling in personalized cancer care. Detailed information about its leadership and corporate history is available through the company’s public filings and corporate disclosures.

Key Stats

• Today's Range: $18.10 to $19.03
• 50-Day Range: $16.85 to $21.24
• 52-Week Range: $16.28 to $42.50
• Volume: 1.87 million shs
• Average Volume: 1.74 million shs
• Market Capitalization: $5.36 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.86
• Consensus Rating: Hold

CAI Stock Analysis - Frequently Asked Questions

How have CAI shares performed this year?

Caris Life Sciences' stock was trading at $26.98 at the beginning of the year. Since then, CAI stock has decreased by 29.8% and is now trading at $18.95.

How were Caris Life Sciences' earnings last quarter?

Caris Life Sciences, Inc. (NASDAQ:CAI) issued its earnings results on Thursday, February, 26th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.27. Caris Life Sciences's quarterly revenue was up 125.4% compared to the same quarter last year.
Read the conference call transcript.

When did Caris Life Sciences IPO?

Caris Life Sciences (CAI) raised $459 million in an initial public offering on Wednesday, June 18th 2025. The company issued 23,529,412 shares at a price of $19.00-$20.00 per share.

Who are Caris Life Sciences' major shareholders?

Top institutional shareholders of Caris Life Sciences include Bank of New York Mellon Corp (0.08%), Sumitomo Mitsui Trust Group Inc. (0.02%), Diversified Trust Co (0.01%) and Hsbc Holdings PLC (0.01%).
View institutional ownership trends.

How do I buy shares of Caris Life Sciences?

Shares of CAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 2/26/2026
• Today: 5/05/2026
• Bank of America Global Healthcare Conference 2026: 5/12/2026
• Goldman Sachs 47th Annual Global Healthcare Conference 2026: 6/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Services
• Industry: Services – Health
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:CAI
• CIK: 2019410
• Web: N/A
• Phone: (866) 771-8946
• Fax: N/A
• Employees: 1,846
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Caris Life Sciences: $28.86
• High Price Target: $38.00
• Low Price Target: $21.00
• Potential Upside/Downside: +52.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 157.92
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.66
• Current Ratio: 7.85
• Quick Ratio: 7.35

Sales & Book Value

• Annual Sales: $812.03 million
• Price / Sales: 6.60
• Cash Flow: $1.62 per share
• Price / Cash Flow: 11.72
• Book Value: $2.05 per share
• Price / Book: 9.24

Miscellaneous

• Outstanding Shares: 282,650,000
• Free Float: N/A
• Market Cap: $5.36 billion
• Optionable: N/A
• Beta: N/A